Search

The Global Vision Database

The overall goal of the Global Vision Database (GVD) [1] is to develop and deploy new and improved evidence on the prevalence of blindness and vision impairment (VI) globally. It is a repository which allows us to assess the causes...

Genetic profiling for personalised healthcare solutions in AMD – an update

Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...

Rare eye diseases: progress continues with authorised orphan medicines and breakthrough technologies

An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...

Neovascular AMD: fresh recommendations underline standards of best practice

The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...

The science of glaucoma management: highlights of the 2020 Moorfields International Glaucoma Symposium

Held earlier this year, the 12th annual Moorfields International Glaucoma Symposium provided a forum for advanced clinical and scientific exchange in glaucoma management. The authors describe the key presentation themes and debates, highlighting specific topics of interest to glaucoma specialists....

Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...

Danger Zone: Miles Hilton-Barber

“Life is either a daring adventure, or nothing at all” – Helen Keller, deafblind American author, activist, and disability rights advocate I have always had a thirst for adventure, even if it has been predominantly from the comfort of my...

Intraocular lens choice in patients who have undergone previous corneal refractive surgery

Patients who underwent vision correction in their 20s to 40s are now entering their 50s and 60s, the typical starting age for cataract development [1]. Consequently, ophthalmologists are increasingly encountering patients whose corneal profiles have been surgically altered, requiring advanced...

Optometrist found guilty of manslaughter

To start our new Optometry section, editor Janet Pooley takes a look at the tragic death of Vincent Barker and asks what lessons can be learned. In August, Optometrist Honey Rose was found guilty of the manslaughter of eight-year-old Vincent...

Four pillars: Exploring eye exigencies

This series explores the four pillars of advanced clinical practice and here, Jem Ann Bautista explores the pillar of clinical practice. As day case theatre practitioners in one of London’s biggest and busiest centres, our team is trained to cater...

In conversation with Fares Antaki: The retinal age gap in schizophrenia

Fares Antaki. Nima Ghadiri (NG): The ‘retinal age gap’ (RAG) is a relatively new concept. Based on your study [1], how confident are you in proposing this as a non-invasive, accessible biomarker for accelerated biological ageing in patients with neuropsychiatric...